Publications from our projects and of relevance
2024
-
- Hoersten J et al. Engineering spacer specificity of the Cre/loxP system
- Maulana TI et al. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
- Cyr-Depauw C et al. Single-Cell RNA Sequencing Reveals Repair Features of Human Umbilical Cord Mesenchymal Stromal Cells
- Noske S et al. Spray-drying of PEI-/PPI-based nanoparticles for DNA or siRNA delivery
- Eitler J et al. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
- Mukhametzyanova L et al. Activation of recombinases at specific DNA loci by zinc-finger domain insertions
- Towers R et al. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype
- Nirmala SS at el. Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity
- Zitzmann FD et al. Microcavity well-plate for automated parallel bioelectronic analysis of 3D cell cultures
- Walther M et al. Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6
2023
-
- Loureiro LR et al. Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment
- Soto KEG et al. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells
- Nelde A et al. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells
- Rasche L et al. CAR T-Cell Therapy in Multiple Myeloma: Mission Accomplished?
- Liebers N et al. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
- Eckhardt JN et al. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
- Ciulean IS et al. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
- Ammar D et al. Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations
- Dragon AC et al. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
- Kröger N et al. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients less than 60 years of age: a prospective phase II study
- Platzbecker U et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
- Leypoldt L et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
- Stelljes M et al. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL
- Bischof L et al. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
- Ruscher C et al. Ecological and clinical evidence of the establishment of West Nile virus in a large urban area in Europe, Berlin, Germany, 2021 to 2022
- Rovó A et al. Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT
- Staudt S et al. Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy
- Rupp L et al. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy
- Mai EK et al. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
- Emde-Rajaratnam M et al. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
- Kovtun I et al. Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
- Schmitt et al. Quantification of evolved DNA-editing enzymes at scale with DEQSeq.
- Becker et al. Development of large-scale expansion protocol for NKG2C-positive NK cells for treatment of glioblastoma.
- Shankar NM et al. Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer.
- Nacasaki Silvestre R et al. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo.
- Kegler A et al. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
- Kandalla PK et al. M-CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation.
- Ruhnke Let al. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial.
- Weller JF et al. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study.
- Peschke JC et al. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
- Glatte B et al. Teclistamab impairs detection of BCMA CAR-T cells.
- Heim C et al. ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
- Ullrich E et al. Editorial: Translating NK cell scientific research to clinical product manufacturing.
- Fischer L et al. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
- Busch CJ et al. Isolation, Ex Vivo Expansion, and Lentiviral Transduction of Alveolar Macrophages.
- Platzbecker U et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
- Devillier R et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.
- Kayser S et al. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
- Platzbecker U et al. Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
- Eckardt JN et al. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification.
- Bauer K et al. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS.
- Schneider M et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS.
- Hysenaj L et al. CD150-dependent hematopoietic stem cell sensing of Brucella instructs myeloid commitment.
- Zapata Bonilla SA et al. Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study.
- Rojo-Romanos T et al. Precise excision of HTLV-1 provirus with a designer-recombinase.
- Rewersdorf JP et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
- Stahl M et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
- Sandoval Bojórquez DI et al. Correction to Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies.
- Sauta E et al. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
- Itzykson R et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
- Bornhäuser M. T cells reloaded after allogeneic HCT.
- Okonechnikov K et al. 3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma.
- Hysenaj L et al. CD150-dependent hematopoietic stem cell sensing of Brucella instructs myeloid commitment.
- Zimmermann R et al. Discriminant Principal Component Analysis of ToF-SIMS Spectra for Deciphering Compositional Differences of MSC-Secreted Extracellular Matrices.
- Oberbach A et al. Four decades of experience of prosthetic valve endocarditis reflect a high variety of diverse pathogens.
- Graninger M et al. Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients.
- Korovina I et al. Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
- Eckardt JN et al. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.
- Chihara D et al. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
- Georgi JA et al. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.
- Braun T et al. Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency.
- Saleh HA et al. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
- Rojo-Romanos et al. Precise excision of HTLV-1 provirus with a designer-recombinase.
- Mircetic et al. CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.
- Mian et al. Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia.
- Kronstein-Wiedemann et al. Novel evidence that the ABO blood group shapes erythropoiesis and results in higher hematocrit for blood group B carriers.
- Nauber et al. Medical microrobots in reproductive medicine from the bench to the clinic.
- Bornhäuser et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
- Zhou at al. A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia.
- Scheller et al. Engineering CD20 CARs with a Twist.
- Arndt C et al. Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy
- Zeidan et al. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
- Baer et al. Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?
- Gainullina et al. Network analysis of large-scale ImmGen and Tabula Muris datasets highlights metabolic diversity of tissue mononuclear phagocytes.
- Eckardt et al. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
- de Laval et al. C/EBPβ-Dependent Epigenetic Memory Induces Trained Immunity in Hematopoietic Stem Cells.
- Mai et al. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
- Denkinger et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
2022
-
- Schmitt aet al. Prediction of designer-recombinases for DNA editing with generative deep learning.
- Jentzsch et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation.
- Körper et al. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.
- Janssen et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
- Othman et al. Overlapping features of therapy-related and de novoNPM1-mutated AML.
- Efficace et al. Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
- Blache et al. Potential solutions for manufacture of CAR T cells in cancer immunotherapy
- Sayed et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing
- Ding et al. DNA methylation–independent long-term epigenetic silencing with dCRISPR/Cas9 fusion proteins
- Subramanian et al. Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo
- Rutella et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia
- Kunadt et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
- Lansing et al. Correction of a Factor VIII genomic inversion with designer-recombinases
- Teipel et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR-T-cell treatment
- Seif et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models
- Lock et al. Automated, scaled, transposon-based production of CAR T cells
- Platzbecker et al. Luspatercept in patients with non-transfusion dependent β-thalassaemia
- García-Guerrero et al. ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells
- Nguyen-Le et al. Nanosensors in clinical development of CAR-T cell immunotherapy
- Peng et al. ROR1-targeting switchable CAR-T cells for cancer therapy
- Röhnert et al. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
- Nagler et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis
- Hayden et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
- Locke et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- Saini et al. Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies
- Taube et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
- Garcia-Manero at al. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
- Weidner et al. Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
- Bethge et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
- Stubbins et al. Inflammation and myeloid malignancy: Quenching the flame
- Hartmann et al. Compartment-specific mutational landscape of clonal hematopoiesis
- Campos Ramos et al. The era of in vivo T cell engineering
- Jayavelu et al. The proteogenomic subtypes of acute myeloid leukemia
- Eckardt et al. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
- Merz et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma
- Mank et al. Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial
- Hernández-Malmierca et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool
- Braun et al. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia
- Xu et al. A Self-Assembled Matrix System for Cell-Bioengineering Applications in Different Dimensions, Scales, and Geometries
- Guedan et al. Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
- Kubasch et al. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
- Donnadieu et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- Hoersten et al. Pairing of single mutations yields obligate Cre-type site-specific recombinases
- Récher et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
- Eckardt et al. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
- Medler et al. CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
- Komrokji et al. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
- Lückemeier et al. Global k off -rates of polyclonal T-cell populations merge subclonal avidities and predict functionality
- Božić et al. Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
- Pleasca I et al. Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma
- Zanotti et al. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
- Damaschin et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
- Nguyen-Le et al. Nanosensors in clinical development of CAR-T cell immunotherapy
2021
-
- von Bonin et al. Clonal hematopoiesis and its emerging effects on cellular therapies
